Fresenius

Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition

Retrieved on: 
Monday, November 23, 2020
Nutrition, Health, Branches of biology, Parenteral nutrition, American Society for Parenteral and Enteral Nutrition, Fresenius, European Society for Clinical Nutrition and Metabolism, Omega-3 fatty acid, Fatty acid, Lipid, Journal of Parenteral and Enteral Nutrition, Calea UK

To support continuous health care professional (HCP) education on omega-3 fatty acids in clinical nutrition, the American Society for Parenteral and Enteral Nutrition (ASPEN) has partnered with Fresenius Kabi to create the Omega-3 Fatty Acids Key Expert Interview Series, which includes five interviews addressing important aspects of omega-3 fatty acids impacting patient care.

Key Points: 
  • To support continuous health care professional (HCP) education on omega-3 fatty acids in clinical nutrition, the American Society for Parenteral and Enteral Nutrition (ASPEN) has partnered with Fresenius Kabi to create the Omega-3 Fatty Acids Key Expert Interview Series, which includes five interviews addressing important aspects of omega-3 fatty acids impacting patient care.
  • Clinicians can also watch previous ASPEN webinars on omega-3 fatty acids:
    Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition: Focus on Critical Care and Major Surgery
    The digital interviews and past webinars are supported by global clinical nutrition leader, Fresenius Kabi.
  • The supplement of the 2020 Journal of Parenteral and Enteral Nutrition Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice was also developed on the topic of omega-3 fatty acids with support from Fresenius Kabi.
  • Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi and ASPEN partner for an expert interview series on omega-3 fatty acid containing parenteral nutrition

Retrieved on: 
Monday, November 23, 2020
Nutrition, Health, Branches of biology, Parenteral nutrition, American Society for Parenteral and Enteral Nutrition, Fresenius, European Society for Clinical Nutrition and Metabolism, Omega-3 fatty acid, Fatty acid, Lipid, Journal of Parenteral and Enteral Nutrition, Calea UK

To support continuous health care professional (HCP) education on omega-3 fatty acids in clinical nutrition, the American Society for Parenteral and Enteral Nutrition (ASPEN) has partnered with Fresenius Kabi to create the Omega-3 Fatty Acids Key Expert Interview Series, which includes five interviews addressing important aspects of omega-3 fatty acids impacting patient care.

Key Points: 
  • To support continuous health care professional (HCP) education on omega-3 fatty acids in clinical nutrition, the American Society for Parenteral and Enteral Nutrition (ASPEN) has partnered with Fresenius Kabi to create the Omega-3 Fatty Acids Key Expert Interview Series, which includes five interviews addressing important aspects of omega-3 fatty acids impacting patient care.
  • Clinicians can also watch previous ASPEN webinars on omega-3 fatty acids:
    Expert Consensus on Omega-3 Fatty Acids in Parenteral Nutrition: Focus on Critical Care and Major Surgery
    The digital interviews and past webinars are supported by global clinical nutrition leader, Fresenius Kabi.
  • The supplement of the 2020 Journal of Parenteral and Enteral Nutrition Lipids in Parenteral Nutrition: Translating Guidelines into Clinical Practice was also developed on the topic of omega-3 fatty acids with support from Fresenius Kabi.
  • Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi Issues Voluntary Nationwide Recall of a Single Lot of Dexmedetomidine Hydrochloride Injection Due to Cross-Contamination of Lidocaine

Retrieved on: 
Thursday, November 19, 2020
FDA, Pharmaceutical, Health, Surgery, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Germany, Companies, Industries, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Germany, Companies, Industries

Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing any affected lots, and to return the product to Fresenius Kabi.

Key Points: 
  • Distributors should notify their customers and direct them to quarantine and discontinue distributing or dispensing any affected lots, and to return the product to Fresenius Kabi.
  • The recall letter and response form are available at https://www.fresenius-kabi.com/us/pharmaceutical-product-updates .
  • Customers with questions regarding this recall may contact Fresenius Kabi at 1-866-716-2459 Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Time.
  • Or, contact Fresenius Kabi at 1-800-551-7176, Monday through Friday, during the hours of 8:00 a.m. to 5:00 p.m. Central Time or via email at:

Vizient Announces Novaplus Enhanced Supply Agreement with Fresenius Kabi for 7 Additional Essential Medications

Retrieved on: 
Thursday, November 19, 2020
Hospitals, Health, Pharmaceutical, Practice Management, Medical Supplies, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Pharmacy, Life sciences, Germany, Industries, Vizient, Inc., Vizient Novaplus and the Novaplus Enhanced Supply Program

Vizient, Inc. today announced an agreement with Fresenius Kabi to add an additional seven medications to its Novaplus Enhanced Supply program , part of Vizients private label pharmacy solution.

Key Points: 
  • Vizient, Inc. today announced an agreement with Fresenius Kabi to add an additional seven medications to its Novaplus Enhanced Supply program , part of Vizients private label pharmacy solution.
  • The agreement brings an additional 4.5 million units of product across the seven medications including four that greatly impact the pediatric patient population.
  • Novaplus Enhanced Supply program now includes a total of 31 molecules with over 53 million units of additional inventory.
  • Fresenius Kabi was the first manufacturer to participate in Novaplus Enhanced Supply when it signed an agreement for six essential medications late last year.

VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement

Retrieved on: 
Thursday, November 19, 2020
Hospitals, Pharmaceutical, Health, Cardiology, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Vifor Pharma, Companies, Industries, Germany

Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa across China.

Key Points: 
  • Under the agreement, Fresenius Kabi will have the exclusive right to distribute and sell Veltassa across China.
  • Stefan Schulze, CEO of Vifor Pharma Group comments, We are delighted to expand VFMCRPs collaboration with Fresenius Kabi.
  • The excellent commercial infrastructure, the well established relationships in nephrology and our existing successful collaboration make Fresenius Kabi our partner of choice to provide Veltassa to patients.
  • Oskar Haszonits, President Region Asia Pacific of Fresenius Kabi said, This agreement is an important step in intensifying our collaboration and relationship with VFMCRP in nephrology.

ProvideGx® Partners with Fresenius Kabi to Help Stabilize Supply of Heparin, a Vital Medication

Retrieved on: 
Wednesday, November 18, 2020
General Health, Other Health, Hospitals, Health, Pharmaceutical, Medicine, Clinical medicine, Intravenous fluids, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Health care, Heparin, Intravenous therapy

(NASDAQ: PINC), through its ProvideGx program, has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.

Key Points: 
  • (NASDAQ: PINC), through its ProvideGx program, has partnered with Fresenius Kabi to supply pre-filled, single-use IV bags of heparin sodium injection, USP to healthcare providers, helping to stabilize the long-term supply of a medication that is necessary when performing a number of hospital inpatient procedures.
  • As COVID-19 cases increase across the country, the partnership between Premier and Fresenius Kabi will help avoid shortages for the benefit of the patients who need this life-saving drug.
  • To help mitigate this problem and assure adequate supply to meet a potential future surge in demand, Fresenius Kabi sources its raw materials from multiple regions.
  • Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi Announces Inductees to Blood Donation Hall of Fame

Retrieved on: 
Monday, November 16, 2020
Medical Supplies, Health, Hospitals, Surgery, Practice Management, General Health, Transfusion medicine, Hematology, Bad Homburg vor der Höhe, Fresenius, Societates Europaeae, Branches of biology, Medicine, Clinical medicine, Blood donation, the need for blood and blood donation, Fresenius Kabi

View the full release here: https://www.businesswire.com/news/home/20201116005181/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201116005181/en/
    The newest inductees to the Fresenius Kabi Blood Donation Hall of Fame are recognized for their passion and commitment to blood donation whether through their own donations or by educating and encouraging others to donate.
  • For more than 20 years, Fresenius Kabi has worked shoulder-to-shoulder with blood centers, donors and volunteers to help ensure patients have access to blood.
  • A person may only be inducted into the Fresenius Kabi Blood Donation Hall of Fame once.
  • Nominations for the 2021 Fresenius Kabi Donation Hall of Fame are due by June 11, 2021.

Envision Healthcare Announces New Revenue Cycle Management Leadership

Retrieved on: 
Monday, November 9, 2020
Other Professional Services, Managed care, Surgery, General Health, Health, Hospitals, Professional services, Other Health, Bad Homburg vor der Höhe, Healthcare in the United States, Revenue Cycle Management, Fresenius, Envision, Germany, Health care, Health

Envision Healthcare, a leading national medical group, today announced a new addition to its leadership team.

Key Points: 
  • Envision Healthcare, a leading national medical group, today announced a new addition to its leadership team.
  • Ashish Ash Goulatia joins the organization as President of Revenue Collections and Executive Vice President of Technology Enablement, effective December 1, 2020.
  • Goulatia will head Envisions Revenue Cycle Management (RCM) function and chair the Revenue Operations Committee.
  • Goulatia joins Envision from Fresenius Medical Care, where he most recently served as Senior Vice President, Finance and led revenue cycle operations.

DGAP-News: Fresenius Medical Care AG & Co. KGaA continues solid revenue and strong earnings growth in the third quarter

Retrieved on: 
Thursday, October 29, 2020
Bad Homburg vor der Höhe, Foreign exchange market, Economies, Fresenius, Societates Europaeae, Euro, Exchange rate

Despite a sizable headwind from exchange rates, revenue was stable and amounted to EUR 4,414 million (+6% at constant currency).

Key Points: 
  • Despite a sizable headwind from exchange rates, revenue was stable and amounted to EUR 4,414 million (+6% at constant currency).
  • Health Care Services revenue remained stable despite the negative effects from exchange rates and amounted to EUR 3,499 million (+6% at constant currency).
  • These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission.
  • Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius Medical Care North America Presents New Insights Related to COVID-19 and Dialysis Innovations at Kidney Week 2020

Retrieved on: 
Thursday, October 22, 2020
Medicine, Bad Homburg vor der Höhe, Health care, Clinical medicine, Membrane technology, Private providers of NHS services, National Kidney Foundation, Phosphate binder, Dialysis, Fresenius Medical Care, Fresenius, Kidney

These publications include new insights related to COVID-19, phosphate binders, a new dialysis system under development, and new software to attain relative blood volume.

Key Points: 
  • These publications include new insights related to COVID-19, phosphate binders, a new dialysis system under development, and new software to attain relative blood volume.
  • "These insights showcase the breadth and depth of our research team, highlighting the many ways that we are working to advance kidney care."
  • The annual symposium, reimagined virtually for 2020, is one of the most influential gatherings of kidney professionals in the world.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.